Hemostemix Inc.

HEM

CA4236943060

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 12:01:10 2024-04-16 pm EDT			5-day change	1st Jan Change
0.055 ^CAD	0.00%		-8.33%	-21.43%

Feb. 06	Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences	CI
2023	Hemostemix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Hemostemix Inc.

Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences	Feb. 06	CI
Hemostemix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 29	CI
Hemostemix Inc. Announces That 4Th Heart Study Published in Stem Cell Research & Therapy Confirms Treatment for Heart Disease	23-10-31	CI
Hemostemix Closed Private Placement	23-10-03	MT
Hemostemix Inc. announced that it has received CAD 0.320385 million in funding	23-10-02	CI
Hemostemix Inc. announced that it expects to receive CAD 0.325125 million in funding	23-09-27	CI
Hemostemix Inc. announced that it has received CAD 0.72754 million in funding	23-09-26	CI
Hemostemix Inc. Announces Its Study of NCP-01 Supporting Brain Computer Interfaces Has Been Submitted for Peer Review Publication	23-09-15	CI
Hemostemix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-28	CI
Hemostemix Inc. Submits its Retrospective Heart Study to Leading Stem Cell Journal	23-08-10	CI
Hemostemix Completes Private Placement; Down 4.2%	23-06-28	MT
Hemostemix Inc. announced that it has received CAD 0.40354 million in funding	23-06-27	CI
Transcript : Hemostemix Inc. - Shareholder/Analyst Call	23-06-09
Hemostemix Inc. announced that it expects to receive CAD 1.2 million in funding	23-05-31	CI
Hemostemix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29	CI
Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-01	CI
Hemostemix Inc. announced that it has received CAD 0.7624 million in funding	23-03-20	CI
Hemostemix Inc. announced that it expects to receive $17.5 million in funding	23-03-06	CI
Hemostemix Inc. announced that it expects to receive CAD 3.36 million in funding	23-01-31	CI
Hemostemix Announces Award of Japanese Patent	23-01-26	MT
Hemostemix Hiring Four Biotechnologists in Montreal, Says Applying for Grants to Fund up to 75% of 5-Year Costs	23-01-23	MT
Hemostemix Announces Letter of Commitment For $250,000 of Funding by McGill University Health Centre Foundation	23-01-19	MT
Hemostemix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-29	CI
Hemostemix Inc. Announces Evolution of Patented Automated Cell Therapy System	22-11-15	CI
Hemostemix Announces NCP-01 Study to Address Pain	22-10-19	MT

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patientâs blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patientâs blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.

Sector

Biotechnology & Medical Research

Calendar

2024-04-29 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HEMOSTEMIX INC.	-21.43%	3.48M
VERTEX PHARMACEUTICALS INCORPORATED	-2.96%	103B
REGENERON PHARMACEUTICALS, INC.	+2.13%	96.56B
ARGENX SE	+1.72%	22.61B
BIONTECH SE	-17.77%	21.18B
GENMAB A/S	-4.50%	19.07B
WUXI APPTEC CO., LTD.	-41.75%	16.53B
BEIGENE, LTD.	-25.46%	14.46B
NEUROCRINE BIOSCIENCES, INC.	+2.49%	13.25B
SAREPTA THERAPEUTICS, INC.	+22.42%	11.1B